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Results From expert opinion, five parameters emerged as 
the best overall indicators to evaluate disease activity: insu-
lin-like growth factor I (IGF-I) level, tumor status, presence 
of comorbidities (cardiovascular disease, diabetes, sleep 
apnea), symptoms, and health-related quality of life. In the 
validation study, IGF-I and tumor status became the pre-
dominant parameters selected for classification of patients 
with moderate or severe disease activity. If IGF-I level was 
≤1.2x upper limit of normal and tumor size not significantly 
increased, the remaining three parameters contributed to the 
decision in a compensatory manner.
Conclusion The validation study underlined IGF-I 
and tumor status for routine clinical decision-making, 
whereas patient-oriented outcome measures received less 
medical attention. An Acromegaly Disease Activity Tool 
(ACRODAT) is in development that might assist clinicians 
Abstract 
Purpose Despite availability of multimodal treatment 
options for acromegaly, achievement of long-term disease 
control is suboptimal in a significant number of patients. 
Furthermore, disease control as defined by biochemical nor-
malization may not always show concordance with disease-
related symptoms or patient’s perceived quality of life. We 
developed and validated a tool to measure disease activity in 
acromegaly to support decision-making in clinical practice.
Methods An international expert panel (n = 10) convened 
to define the most critical indicators of disease activity. 
Patient scenarios were constructed based on these chosen 
parameters. Subsequently, a panel of 21 renowned endocri-
nologists at pituitary centers (Europe and Canada) catego-
rized each scenario as stable, mild, or significant disease 
activity in an online validation study.
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towards a more holistic approach to patient management in 
acromegaly.
Keywords Acromegaly · AcroQoL · Patient-reported 
outcomes · ACRODAT
Introduction
Acromegaly is a rare chronic disease associated with meta-
bolic abnormalities, risk of cardiovascular complications, 
slowly progressive, irreversible disfigurement, and increased 
mortality [1]. In more than 99% of patients, acromegaly is 
the result of a growth hormone (GH)-producing pituitary 
tumor, which causes elevated circulating levels of GH and 
insulin-like growth factor-I (IGF-I) [2]. Visible signs include 
enlarged hands and feet, enlarged jaw and facial bones, thick-
ening of the skin, and excessive sweating. Common patient 
complaints also include headache, joint pain, fatigue and 
sleep disturbances [1, 2]. Acromegaly has also been associ-
ated with reduced quality of life (QoL) [3], which may show 
improvement with treatment [4–6]. However, patients are 
frequently not diagnosed until 5–10 years after onset [1] and, 
if disease control is not achieved, acromegaly is associated 
with increased mortality and risk of metabolic and cardiac 
complications [1, 7, 8].
Several guidelines for assessment of disease activity are 
available [9, 10]. A widely accepted consensus on criteria 
for cure defines active disease as (1) a random GH >1 μg/L 
and nadir GH after oral glucose tolerance test ≥0.4 μg/L; 
(2) elevated IGF-I; and (3) clinically active. A definition of 
the term “clinically active” is not provided. GH and IGF-I 
are key biochemical parameters to assess disease activity 
in acromegaly, but the variability in assay performance and 
broad normal ranges may limit their predictive value of 
disease control. For patients on pegvisomant (PEGV) treat-
ment, normalization of IGF-I is the only reliable marker of 
disease control, as PEGV blocks the GH receptor and results 
in elevated rather than reduced GH levels [11].
Even when biochemical control is achieved, patients may 
still experience disease-specific symptoms such as fatigue, 
arthralgia, and a generally reduced health status and QoL [6, 
12, 13]. The patients’ own perspectives of their health status 
may therefore be an important additional measure to assess 
the level of disease activity and for clinical decision-making.
In patients with significantly elevated IGF-I levels, the 
treatment goal of achieving biochemical control seems an 
obvious decision [9, 10]. Despite this, acromegaly registries 
have reported failure to fully control IGF-I in more than 30% 
of patients over time [14, 15]. Whether a mild elevation in 
IGF-I level in a patient without symptoms requires treatment 
may be more controversial. The same applies for patients 
with normalized IGF-I levels who have impaired QoL and/
or clinical signs of disease activity.
Our first objective was to convene a panel of acromegaly 
experts to identify the most relevant and meaningful set 
of clinical parameters and their severity level in order to 
define disease activity status of patients with acromegaly. 
Second, we conducted a discrete choice experiment to 
observe the level of agreement between these parameters, 
including defined severity levels, and the treatment goals 
utilized in routine clinical practice by endocrinologists spe-
cialized in acromegaly. The results are being used to build 
the Acromegaly Disease Activity Tool (ACRODAT) that 
will support objective as well as patient-reported indicators 
of management.
Materials and methods
Identification of key parameters
A panel of 10 experts in the field of endocrinology, neu-
rosurgery, and acromegaly management was convened to 
determine the appropriate health status parameters and 
scoring algorithm for ACRODAT development. During five 
full-day panel meetings over a 2.5-year period, members 
were asked to map all disease parameters associated with 
acromegaly. The combined list was refined based on criteria 
related to their importance in enabling clinical monitoring 
of disease activity, which data would be readily available as 
part of routine clinical practice, the relevance to health status 
focusing on the clinical as well as patient perspective, and 
the responsiveness of these chosen parameters to appropri-
ate clinical action. The panel members were then asked to 
define clinical descriptions for the three levels of severity of 
each individual parameter: level 1: the patient is adequately 
controlled; level 2: the patient shows mild disease activity, 
further evaluation of the patient’s condition is needed; level 
3: the patient shows significant disease activity, requiring 
clinical action.
Validation study
The next step in the development of ACRODAT was to eval-
uate the predictive validity of the five selected key parame-
ters and their severity levels by a separate cohort of endocri-
nologists who routinely managed patients with acromegaly 
in clinical practice. The validation study had two main 
objectives: (1) to assess the inter-rater agreement of disease 
activity status among practicing endocrinologists and (2) 
develop and assess a model that predicts renowned endo-
crinologists’ judgment of disease activity status in patients 
with acromegaly, based on a set of hypothetical patient sce-
narios. ICON plc (Dublin, Ireland), an independent contract 
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1 3
research organization, was contracted (project number 0002-
1088) to perform the validation study.
For each scenario, the physicians were asked whether 
the patient (i.e. adults with confirmed diagnosis of acro-
megaly) described by the hypothetical profile was “stable” 
(S: the patient is adequately controlled), had “mild disease 
activity” (M-DA: the patient shows mild disease activity, 
further evaluation of the patient’s condition is needed), or 
had “significant disease activity” (S-DA: the patient shows 
significant disease activity requiring clinical action). The 
three disease activity categories were color-coded as green 
(S), yellow (M-DA), or red (S-DA). The five parameters, 
and three levels within each parameter, produced a total of 
243  (35) possible patient profiles or scenarios. Though some 
scenarios may have reflected a patient profile that would 
unlikely be seen in clinical practice, the expert panel recom-
mended retaining all possible scenarios for completeness 
and to avoid making any assumptions about the feasibility 
of the scenarios.
It was estimated that it would take each physician approx-
imately 1 h to rate a total of 52 scenarios; therefore, the num-
ber of possible scenarios to be rated per individual endo-
crinologist was set at 52. The study was designed to ensure 
sufficient variation and coverage of health parameters in the 
scenarios by using a random selection approach. In addition, 
a subset of scenarios specifically selected to reflect a range 
of health status severity was presented to all participants 
to allow for examination of inter-rater agreement. The 10 
“common” scenarios were selected by the expert panel and 
included clinically plausible scenarios representing a wide 
range of overall health status, from fairly good health (all 
parameters at level 1) to very poor health (all parameters 
at level 3). In the survey, each parameter was color coded 
according to the level of severity as an easy reminder for 
the rater as to the defined differences in level and to reduce 
random error. A summary page was included at the end of 
the survey to allow physicians to review all of their response 
and go back if they wanted to change an answer.
Selection of participants
In all, 42 endocrinologists (at least five per country) were 
identified by the expert panel to be invited to participate. 
Initial solicitation e-mails were sent by the expert panel 
member who had recommended the physician. Those who 
agreed to participate were contacted by ICON via telephone 
or email and screened for eligibility. Endocrinologists had to 
meet the following criteria: (1) worked in a hospital, hospital 
outpatient clinic, or private outpatient clinic; (2) saw at least 
five acromegaly patients annually or, if fewer, supervised 
others who treat acromegaly patients; (3) not familiar with 
ACRODAT or was not involved in extensive development 
activities for ACRODAT prior to this study; (4) able to read 
and understand English; (5) willing and able to participate 
in the study, which involved completing an online survey 
lasting approximately 60 min.
After providing agreement to participate in the study, 
physicians were emailed a link to complete the online sur-
vey. Participants were compensated for their time in com-
pleting the survey.
Sample size
Due to the exploratory nature of this study, formal sample 
size calculations were not considered appropriate. Neverthe-
less, in studies where multivariable modeling is expected to 
be performed, the study should have at least 10 events for 
each variable included in the model. In this study, predictor 
variables comprised the five health status parameters, each 
of which had a three-level ordinal variable. For each health 
status parameter, indicator variables were created for all but 
one of the levels (the referent level S was not coded because 
it is a linear combination of the other levels). Therefore, the 
multivariable model would have 10 variables.
An “event” can be defined as the physician categori-
zation of a hypothetical patient as S (or having M-DA or 
S-DA). An assumption was made that an “event” would 
occur in roughly one-third of the patients (i.e., roughly one-
third of the hypothetical patients would be categorized into 
each of the three possible outcomes), which meant that the 
study would require 300 responses (10 events × 10 varia-
bles ÷ [1/3]). Since the same physician was expected to eval-
uate many different scenarios, observations in the dataset 
were not independent, causing some statistical power to be 
lost. As an attempt to adjust for this potential loss in statisti-
cal power, the number of observations was doubled, result-
ing in a dataset with a minimum of 600 observations. Given 
that 21 physicians were available to evaluate the scenarios, 
the study required each physician to evaluate a minimum of 
29 scenarios (600 ÷ 21).
Statistical analyses
Survey results were analyzed using  SAS® 9.3 (SAS Institute 
Inc, Cary, NC, USA). The Fleiss’ kappa was calculated to 
provide a summary statistical measure for assessing the reli-
ability of agreement between endocrinologists in rating the 
common scenarios. For algorithm development to predict 
disease activity categorization based on values of the five 
health status parameters, a combination of the Classifica-
tion and Regression Tree (CART) method and multivariable 
logistic regression was implemented.
Because the purpose of this analysis was not to test any 
specific hypothesis, no p-values were presented, no signifi-
cance testing was performed, and no adjustments for multi-
ple comparisons were made.
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Results
Key parameters and levels of severity
Five parameters were selected by the panel of acromegaly 
experts as key aspects of the patient’s condition: IGF-I 
level, tumor status, comorbidities, signs and symptoms, 
and health-related QoL (HRQoL). A funnel approach 
was used to crystallize these key parameters from a large 
set of disease parameters (Table 1). Each parameter was 
defined and agreed upon by the panel at three levels of 
severity (Table 2). The IGF-I levels were assigned using 
deviations from normal levels. The tumor status param-
eter was based on results of magnetic resonance imag-
ing and levels were assigned based on a significant mass 
effect resulting in a worsening of vision or a change in 
tumor size and invasiveness over time. The comorbidities 
parameter was assigned based on the presence or absence 
and severity of several acromegaly associated conditions 
(i.e. diabetes, sleep apnea, and cardiac disease). The symp-
toms parameter was the Signs and Symptoms Score (SSS), 
based on an abbreviated version of the original Patient 
Assessed Symptom Questionnaire (PASQ); it is a disease-
specific five items questionnaire, scored 0–8, that consid-
ers headache, perspiration, joint pain, fatigue, and soft 
tissue swelling. The maximum score of 40 is indicative 
of severe signs and symptoms [3]. The HRQoL impair-
ment parameter was based on the standardized total score 
from a validated measure of the Acromegaly Quality of 
Life Questionnaire (AcroQoL). The AcroQoL is a disease-
specific questionnaire covering physical and psychological 
aspects of acromegaly. It comprises 22 questions, each 
having five possible responses, scored 1–5; the maximum 
score of 110 reflects best possible QoL and is quoted as a 
percentage [16]. The parameter of HRQoL was described 
in general terms and the interpretation of scores was based 
on three levels of impairment: none or minimal, moderate, 
and severe. The specific measure was not identified in the 
validation study to avoid response bias based on the clini-
cian’s familiarity with and perceptions of the utility of any 
single instrument.
Validation study
A total of 21 physicians from Canada, France, Germany, 
Italy, Spain, and the United Kingdom completed the inter-
net-based survey in 2015. The overall characteristics of the 
participants are summarized in Table 3. Fourteen of the 21 
endocrinologists worked in a hospital outpatient clinic. On 
average, they reported having more than 20 years of expe-
rience in treating acromegaly and had treated an average 
number of 48 patients with acromegaly annually.
Inter‑rater agreement
Inter-rater agreement was assessed for the subset of sce-
narios (common scenarios) that all participating physicians 
were asked to rate. The extent to which physicians agreed 
on each scenario (how many rater–rater pairs were in agree-
ment relative to the number of all possible rater–rater pairs, 
and represented by Pr in Table 4) varied by scenario. The 
most extreme scenarios—all parameters at the lowest level 
of severity (level 1) or all parameters at the highest level of 
severity (level 3)—had complete agreement among physi-
cians (Pr = 1), with all physicians rating level 1 and level 3 
as S and S-DA, respectively. The Fleiss’ kappa value was 
0.526, which indicated a moderate amount of inter-rater 
agreement. Because a single physician rated one scenario as 
S whereas all other physicians rated this scenario as S-DA, a 
sensitivity analysis on inter-rater agreement was performed, 
excluding this physician. With the outlier removed, a Fleiss’ 
kappa value of 0.549 was observed.
Algorithm development
Of the 21 physicians, 20 evaluated the maximum number of 
scenarios each (52 scenarios), whereas one physician eval-
uated 51 scenarios, yielding a total of 1091 observations. 
The outcome variable was an ordinal three-level physician 
assessment of hypothetical patient condition (disease activ-
ity categorization).
Generally, an IGF-I > 1.2 × upper limit of normal or the 
worst tumor status (both indicated as level 3) tended to have 
high scores for S-DA and very low scores for S. Similar 
patterns for the highest levels of severity were observed for 
comorbidities, symptoms, and HRQoL impairment; how-
ever, the distributions were less extreme. Medium levels of 
severity (level 2) of each health status parameter tended to 
have higher scores for M-DA and S-DA compared with S. 
No apparent trend was observed for the lowest level of sever-
ity (level 1) of the health status parameters.
In the CART decision-tree model, only two of the health 
status parameters had an immediate influence in the ultimate 
disease activity rating: IGF-I and tumor status (see Fig. 1). 
If IGF-I was indicated as level 3, then disease activity was 
immediately rated as S-DA. Otherwise, tumor status was eval-
uated and if it was indicated as level 3, then disease activity 
was similarly rated as S-DA. These straight-away terminal 
nodes in the decision tree based on a level 3 indication of 
either IGF-I or tumor status suggested a non-compensatory 
decision-making process. Regardless of the level of the other 
three clinical parameters, there was no opportunity for them 
to compensate for high levels of IGF-I or tumor status. Hence, 
it was decided that the overall disease activity status would 
be classified as S-DA if either IGF-I or tumor status was 
indicated as level 3. However, if neither of these two health 
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status parameters were indicated as level 3, then the other 
three health status parameters (comorbidities, symptoms, and 
HRQoL), along with the remaining levels of IGF-I and tumor 
status, appeared to operate in a compensatory manner.
To further elucidate the contribution of all parameters, 
logistic regression models were constructed. Multivari-
able logistic regression was performed only on the parts of 
the CART decision tree that were deemed to behave in a 
compensatory manner. Specifically, the independent vari-
ables were the three-level categorical variables related to 
comorbidities, symptoms, and health-related quality of life 
impairment (outlined in Table 2). The outcome variable was 
modeled as two separate binary choices, which may more 
closely resemble what occurs in clinical practice. The first 
choice (Model 1) was whether the patient was considered to 
be S or M-DA/S-DA; that is, whether the patient was stable 
or not. If the physician failed to rate the scenario as S, then 
the second choice (Model 2) was whether the patient was 
considered to be S-DA versus M-DA. To create a single 
scale from both models, the predicted probabilities from 
Model 1 and Model 2 were combined. For each scenario, 
the probability of it being rated as S was defined as the pre-
dicted probability from Model 1, and the probability of it 
being rated as S-DA was defined as the predicted probability 
from Model 2. The probability of each scenario being rated 
as M-DA was then computed as 1 minus the sum of the other 
two probabilities. Hence, for each scenario, the probabilities 
(P) of it being rated as S  (PS), M-DA  (PM−DA), or S-DA 
 (PS−DA) summed to 1.
A single continuous ACRODAT score for each scenario 
was calculated as a weighted average of these single scale 
probabilities  (PS,  PM−DA, and  PS−DA), then transformed onto 
a 0 to 1 scale as follows:
Worked examples for the calculation of the single con-
tinuous ACRODAT score are provided in the “Appendix”. 
It was further decided to classify the overall disease activity 
status for scenarios with an IGF-I and/or tumor status level 
below 3 as M-DA if  PM−DA was higher than  PS, and as S if 
 PS was higher than  PM−DA.
Discussion
The present study shows the development of the ACRODAT 
tool intended to help clinicians in measuring disease activity 
ACRODATScore =
{[(
1 × P
S
)
+
(
2 × P
M−DA
)
+
(
3 × P
S−DA
)]
− 1
}
∕2
Table 2  Five selected parameters and their level of severity
IGF‑I insulin-like growth factor I, ULN upper limit of normal, LLN lower limit of normal, MRI magnetic resonance imaging, SSS Signs and 
Symptoms Score, QoL quality of life, AcroQoL Acromegaly Quality of Life Questionnaire
a The endocrinology experts selected AcroQoL as the most suitable currently available tool to address disease-specific QoL assessment. In order 
to avoid response bias, the term “health-related quality of life” was used in the validation study
Health status parameter Parameter levels
IGF-I 1 = IGF-I is within normal limits
2 = IGF-I exceeds the ULN but not >1.2 × ULN, or is below LLN
3 = IGF-I is significantly elevated, >1.2 × ULN
Tumor status Based on the most current MRI:
1 = Tumor is not visible or has not changed since prior MRI
2 = A slight increase in tumor size (≤20%) is observed
3 = A clinically significant increase in tumor size (>20%) and/or invasiveness is observed since prior MRI 
and/or a worsening in vision is observed
Comorbidities 1 = No diabetes diagnosis, complaints of sleep apnea are absent, and cardiac disease, if present, is well con-
trolled
2 = Diabetes controlled by therapy, with no concomitant complaints of sleep apnea, and cardiac disease, if pre-
sent, is controlled with therapy or no diabetes diagnosis but complaints of sleep apnea and/or cardiac disease 
that is not well controlled with therapy
3 = Diabetes is not well controlled by therapy or diabetes is well controlled, with complaints of moderate to 
severe sleep apnea and/or uncontrolled cardiac disease
Symptoms 1 = Mild: patient reports no or only mild symptoms on SSS (all symptoms rated ≤2)
2 = Moderate: patient reports presence of some symptoms on SSS but no single symptom exceeds a score of 6 
(mild to moderate) and mean score is ≤4 overall
3 = Severe: patient reports significant symptoms on SSS, with mean score >4 or one or more symptoms rated 
>6
Health-related QoL  impairmenta 1 = Patient reports no or minimal impairment in QoL (score ≥60)
2 = Patient reports mild to moderate impairment in QoL (40 ≤ score <60)
3 = Patient reports significant impairment in QoL (score <40)
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among patients with acromegaly. The funnel approach to 
extract key parameters of disease activity for acromegaly 
from an evidence-based review and consensus to enable 
individualized treatment goals for patients and endocrinolo-
gists was found to be feasible. In addition, the adoption of 
such translation of clinical targets, which also includes the 
patient’s perspective through patient-reported outcomes such 
as SSS and AcroQoL, provides a holistic approach to dis-
ease management. Consideration in selection of these key 
parameters included their ease of availability in routine clini-
cal practice as well as their likelihood of responsiveness to 
available treatments.
The validation study outcome was a confirmation of 
the current status of acromegaly management, which dem-
onstrated a main focus on tumor status and IGF-I value. 
Whether inclusion of patient-reported outcomes as well as 
comorbidity status would improve the quality of clinical 
decision-making remains to be demonstrated, but the tool 
devised from our study facilitates a holistic approach and 
may alert the treating endocrinologist to the patient’s needs 
and comorbidity status.
In the validation study, IGF-I and tumor status defini-
tions for the highest level of severity (level 3) were gen-
erally accepted and validated as representing significant 
disease activity requiring clinical action. If neither of these 
two health status parameters were indicated as level 3, then 
the other three health status parameters (comorbidities, 
symptoms, and HRQoL) along with the remaining levels of 
IGF-I and tumor status appeared to operate in a compensa-
tory manner.
When the pituitary tumor mass effect is clinically insig-
nificant and the lesion is considered to be stable, remission 
in acromegaly is often defined exclusively in biochemical 
terms. Although biochemical control is considered key to 
achieve remission/cure, it does not guarantee symptom 
relief and the general well-being of the patient. Symptoms 
of acromegaly and reduced QoL may persist despite normal 
post-treatment serum IGF-I levels [6, 12, 13]. The benefits to 
patients and their QoL are therefore a relevant consideration 
in the medical management of acromegaly, as also proposed 
in recent guidelines [10]. It is also recommended to closely 
monitor and rigorously manage patients with acromegaly for 
associated comorbidities [9].
When considering both GH and IGF-I, elevated IGF-I 
levels were regarded by the panel to be the preferred bio-
chemical predictor for disease activity in acromegaly, and 
Table 3  Characteristics of the participants in the validation study
SD standard deviation
Physician characteristic
Males, n (%) 14 (66.6)
Females, n (%) 7 (33.3)
Age, years
 Median (range) 51 (40–67)
 Mean (SD) 51.8 (7.4)
Country of origin, n (%)
 Spain 7 (33.3)
 Canada 6 (28.6)
 United Kingdom 2 (9.5)
 Italy 2 (9.5)
 Germany 2 (9.5)
 France 2 (9.5)
Unique acromegaly patients seen annually, n
 Median (range) 40 (5–140)
 Mean (SD) 48.3 (34.3)
Location of treatment, n (%)
 Hospital outpatient clinic 14 (66.6)
 Hospital 5 (23.8)
 Private outpatient clinic 2 (9.5)
No. of years treating acromegaly patients
 Median (range) 20 (10–35)
 Mean (SD) 21.2 (8.8)
Table 4  Inter-rater agreement of common scenarios
Pr denotes the extent to which physicians agree on each scenario 
(physician pairs in agreement relative to the number of all possible 
pairs), ranging from 0 to 1 and with 1 representing complete agree-
ment
Pc denotes the proportion of all physician assessments that were 
assigned to each category. For instance, for the outcome “stable,” 
it equals the total number of physician assessments rated as stable 
(n = 62), divided by the total number of possible physician assess-
ments (10 × 21 = 210)
Fleiss’ kappa statistic (κ) provides a summary statistical measure for 
assessing the reliability of agreement between physicians in rating 
common scenarios
S stable, M‑DA mild disease activity, S‑DA significant disease activity
a Bracketed numbers refer to the level of severity for each of the health 
status parameters. As an example, scenario 166 [31121] as shown in 
Table  4 describes a hypothetical patient case with IGF-I at level 3, 
Tumor status at level 1, Comorbidities at level 1, Symptoms at level 2 
and QoL at level 1. For a description of the levels, see Table 2
Scenarioa S M-DA S-DA Pr
Scenario 1 [11111] 21 0 0 1.000
Scenario 5 [11122] 17 4 0 0.676
Scenario 11 [11212] 14 7 0 0.533
Scenario 59 [13122] 1 9 11 0.433
Scenario 92 [21212] 4 16 1 0.600
Scenario 122 [22222] 1 17 3 0.662
Scenario 166 [31121] 2 8 11 0.400
Scenario 203 [32222] 1 3 17 0.662
Scenario 230 [33222] 1 0 20 0.905
Scenario 243 [33333] 0 0 21 1.000
Pc 0.295 0.305 0.400 κ = 0.526
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reliable, age-related normative data have recently become 
available for IGF-I assays [17]. For patients receiving PEGV 
treatment, normalization of IGF-I is the only available bio-
chemical marker of disease control [11]. Over the years, con-
sensus statements have recommended varying levels of GH 
to represent control whereas IGF-I guidance has remained 
the same, stating that the age-adjusted levels should be in 
the normalized range [9].
Diabetes, cardiovascular disease, and sleep apnea were 
selected as the key comorbidities, as these can be managed 
and improved upon by appropriate modification of treat-
ments used for acromegaly and for comorbidity-specific 
treatments. Other comorbidities characteristic to acromeg-
aly, such as arthritis, osteoporosis, and colonic polyps, 
were not selected. Although prevalent, these comorbidi-
ties are less modifiable by treatments used for acromegaly, 
especially in advanced disease state. Cardiovascular dis-
ease is considered a key factor because of the heightened 
risk for cardiovascular complications and consequent need 
for early identification and treatment. Diabetes, even if 
it was adequately controlled with anti-diabetic medica-
tion, was considered by the expert panel as an independ-
ent risk factor requiring further evaluation. Obstructive 
sleep apnea is a comorbidity that may occur in 25–60% of 
patients, and may contribute to hypertension and cardio-
vascular disease. The apnea-hypopnea index may improve 
during effective treatment of acromegaly [18, 19]. To 
which degree disease control and treatment approach are 
related to QoL is still a matter of debate. Rowles et al. [3] 
found no correlation between biochemical control and any 
measure of QoL. QoL is a multifactorial issue that needs 
an individualized approach for detection and management 
[20].
Despite the availability of different treatment options, 
patients do not always achieve disease control as defined by 
the treatment guidelines. Success of surgery is very much 
dependent on the type of tumor (microadenoma vs. macroad-
enoma, invasion of cavernous sinus) and the experience of 
the pituitary surgeon [21, 22]. Medical therapy with dopa-
mine agonists or somatostatin analogs results in biochemi-
cal control in only 20–40% of drug-naïve patients [23–26]. 
Second line medical treatment with PEGV has been shown 
to normalize IGF-I levels in 75–97% of patients [27–29], but 
is often considered a last-resort treatment. Radiotherapy is 
considered a viable therapy in only a subset of patients due 
to its long-term side effects [9]. Other factors may contribute 
to the lack of disease control in some patients: the patient’s 
reluctance to escalate therapy, non-compliance, discordant 
levels of IGF-I and GH in the individual patient, and modifi-
cations in pharmacotherapy [15]. This underlines the impor-
tance of continuous monitoring of the patient’s condition.
One important limitation of the validation study is that 
other factors not considered in ACRODAT may influence 
the overall disease activity status of the patient. It goes with-
out saying that physicians should always utilize their own 
knowledge and judgment when assessing the disease activ-
ity of their patients and making adjustments to their plan of 
treatment.
Fig. 1  CART decision-tree model. IGF‑I insulin-like growth factor-I, M‑DA mild disease activity, S stable, S‑DA significant disease activity, 
ULN upper limit of normal
Pituitary 
1 3
The next step in the ACRODAT development project 
will be to prospectively evaluate whether patients moni-
tored by ACRODAT, with appropriate clinical decisions 
based on disease activity status, benefit from improved 
treatment outcomes both in the short- and long-term. The 
resulting algorithm that yielded an overall continuous 
score (ACRODAT score) to rate overall disease activity on 
a 0–1 scale may be a beneficial tool for physicians to use 
in evaluating patients with acromegaly. The tool’s design 
will not be to provide any treatment recommendations; 
however, it will provide guidance as to whether clinical 
action is deemed necessary for one or more of the key 
parameters.
In summary, we were able to develop a disease activity 
tool specific for acromegaly based on five easily measurable 
key outcome disease parameters. Monitoring changes at reg-
ular intervals may facilitate better treatment decisions and 
support a holistic approach to acromegaly disease manage-
ment.  SAGIT®, another clinician-reported outcome instru-
ment currently in development, reaffirms the need for such 
instruments to support acromegaly management [30]. The 
unique methodology applied to the development of ACRO-
DAT may also be useful in other rare disease settings.
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Appendix
Worked examples for the calculation of the single continuous 
ACRODAT score based on two of the 10 common scenarios. 
Scenario 92: IGF-I: level 2; Tumor size: level 1; Comorbidi-
ties: level 2; Symptoms: level 1; QoL: level 2. Physicians 
(n = 21) rated this hypothetical patient case as follows: sta-
ble (n = 4), mild disease activity (n = 16), significant disease 
activity (n = 1). Based on multivariable logistic regression, 
the predicted probability of the scenario being rated as S 
versus M-DA/S-DA was 0.133. The predicted probability 
of the scenario being rated as S-DA versus M-DA (among 
non-S) was 0.06. Therefore, the predicted probability of the 
scenario being rated as M-DA was 1 − (0.06 + 0.133) = 0.807 
and the ACRODAT Score = {[(1 × 0.133) + (2 × 0.807) +  (
3 × 0.06)] − 1}/2 = 0.463. As  PM−DA is higher than  PS, the 
overall disease activity is classified as M-DA.
Scenario 243: IGF-I: level 3; Tumor size: level 3; Comor-
bidities: level 3; Symptoms: level 3; QoL: level 3. All physi-
cians rated this hypothetical patient case as having signifi-
cant disease activity. The  PS−DA is 1,  PS and  PM−DA are both 
0 and the resulting ACRODAT Score = {[(1 × 0) + (2 × 0) + 
(3 × 1)] − 1}/2 = 1. As IGF-I and Tumor size are both indi-
cated as 3, the overall disease activity is classified as S-DA.
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